Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David J. Kerr

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Oncology (Williston Park, N.Y.)|May 17, 2002
Capecitabine/irinotecan combination regimens in colorectal cancerDavid J Kerr
Nature Reviews. Clinical Oncology|September 3, 2014
Policy: EU data protection regulation--harming cancer researchDavid J Kerr
Nature Clinical Practice. Oncology|November 3, 2005
Targeting angiogenesis in cancer: clinical development of bevacizumabDavid J Kerr
Nature Clinical Practice. Oncology|October 22, 2008
Capecitabine: have we got the dose right?Rachel Midgley, David J Kerr
Nature Clinical Practice. Oncology|August 4, 2005
Adjuvant chemotherapy for stage II colorectal cancer: the time is right!Rachel Midgley, David J Kerr
Expert Opinion on Drug Metabolism & Toxicology|June 13, 2015
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developmentsDavid J Bell, David J Kerr
Critical Reviews in Oncology/Hematology|November 5, 2002
Ras as a target in cancer therapyRachel S Midgley, David J Kerr
Rare Tumors|December 9, 2010
Malignant peritoneal mesothelioma. Is there a new treatment?Kakil Ibrahim Rasul, David J Kerr
Expert Review of Anticancer Therapy|February 25, 2003
Immunotherapy for colorectal cancerRachel S Midgley, David J Kerr
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Oncology (Williston Park, N.Y.)|May 17, 2002
Capecitabine/irinotecan combination regimens in colorectal cancerDavid J Kerr
Nature Reviews. Clinical Oncology|September 3, 2014
Policy: EU data protection regulation--harming cancer researchDavid J Kerr
Nature Clinical Practice. Oncology|November 3, 2005
Targeting angiogenesis in cancer: clinical development of bevacizumabDavid J Kerr
Nature Clinical Practice. Oncology|October 22, 2008
Capecitabine: have we got the dose right?Rachel Midgley, David J Kerr
Nature Clinical Practice. Oncology|August 4, 2005
Adjuvant chemotherapy for stage II colorectal cancer: the time is right!Rachel Midgley, David J Kerr
Expert Opinion on Drug Metabolism & Toxicology|June 13, 2015
Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developmentsDavid J Bell, David J Kerr
Critical Reviews in Oncology/Hematology|November 5, 2002
Ras as a target in cancer therapyRachel S Midgley, David J Kerr
Rare Tumors|December 9, 2010
Malignant peritoneal mesothelioma. Is there a new treatment?Kakil Ibrahim Rasul, David J Kerr
Expert Review of Anticancer Therapy|February 25, 2003
Immunotherapy for colorectal cancerRachel S Midgley, David J Kerr
Acta Oncologica (Stockholm, Sweden)|August 6, 2003
Colorectal cancerShibani Nicum, Rachel Midgley, David J Kerr
Pageof 9